Growth-hormone-derived peptide studied for effects on fat metabolism
Clinical research
Read the profile Peptide profile
Cagrilintide
Long-acting amylin analogue
Clinical research
Science, with its context intact.What to knowThe evidence
The evidence
in perspective.
A randomized phase 2 trial studied weight management. Human trial evidence is not product approval. FDA states that cagrilintide cannot be used in compounding under federal law.
View the supporting source- Research area
- Metabolic
- Biological target or mechanism
- Long-acting amylin analogue
- Evidence context
- Clinical research
- Availability
- Reference only. Not available for compounding.
From information to a conversationClinical decisions stay
Clinical decisions stay
with clinical professionals.
This profile is a research reference. Your prescriber and pharmacy assess the relevant clinical and dispensing pathway. Inclusion here is not an offer to sell this compound.
